Ulcerative Colitis

There has been interest expressed in both Nuvion and ularitide, for which we have worldwide rights.

I think we have the luxury of not feeling that we need to partner at this point, but we certainly consider those as opportunities," Benner said.

He said the company has no commercial sales force in Europe, so a future partner that could provide that structure would be a plus.

© Reuters 2006.

All Rights Reserved.

Reuters.com Help & Info Careers Reuters journalists are subject to the Reuters Editorial Handbook which requires fair presentation and disclosure of relevant interests.

...

The body may respond to this buildup of bacteria by secreting inflammatory molecules, which accumulate and lead to the chronic inflammation typical of Crohn's.

"Causation of Crohn's disease by failure of the acute inflammatory response would fit very well with the so-called hygiene hypothesis, in which the increased incidence of the disease has been attributed to improved standards of sanitation," the authors wrote, noting that incidence of the disease rose greatly in the latter part of the 20th century.

"These findings provide hope for the development of more effective therapies for Crohn's disease," the authors said.

Current treatments are immunosuppressive, but although they reduce symptoms by dampening the proposed secondary inflammation, they might actually accentuate the underlying immunodeficiency.

A more successful treatment approach might be to introduce IL-8 or other proinflammatory stimuli directly into acute lesions, either by direct enteral administration or through synthesis by genetically modified gut o...

Jacob said he intends to dedicate some of the funds to further development of cancer-fighting compound, Degrasyns, which the Company recently has licensed from the University of Texas' M.

D.

Anderson Cancer Center, one of the world's preeminent research institutions in the field of cancer.

"The anti-cancer activity of Degrasyns relates to its ability to selectively degrade key proteins involved in tumor cell proliferation and survival," he noted.

"This is very significant potentially because these compounds have the potential to treat not only hematological cancers, that is, blood cancers, but also solid tumor cancers, which is a whole other extremely significant area, medically, for the treatment of cancer.

It opens the drug up for a very broad number of potential applications for treatment." In an earlier interview, Dr.

Jacob described the ways in which this private placement funding would accelerate development of Callisto's anticancer drugs, L-Annamycin and Atiprimod, which have advanced to human clinical studies.

The interview is now available free of charge to all interested investors by visiting http://www.smallcapinsights.com.

About Callisto Pharmaceuticals, Inc.

Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions.

Callisto's drug ca...